Lyra Therapeutics Inc. (LYRA)
OTC PINK OTC PINK Primary Summary
Lyra Therapeutics, Inc. (LYRA) Reports Q3 Loss, Lags Revenue Estimates
Lyra Therapeutics, Inc. (LYRA) came out with a quarterly loss of $3.38 per share versus the Zacks Consensus Estimate of a loss of $5.98. This compares to a loss of $9 per share a year ago.
Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Beats Revenue Estimates
Lyra Therapeutics, Inc. (LYRA) came out with a quarterly loss of $5.51 per share versus the Zacks Consensus Estimate of a loss of $5.79. This compares to a loss of $14.5 per share a year ago.
Lyra Therapeutics: Regulatory Pathway For Non-Polyp Patients, An Underappreciated Catalyst
Lyra Therapeutics has lost >90% of its value since announcing the failed ENLIGHTEN-1 trial, despite the recent announcement of a clearly positive ENLIGHTEN-2. Considering a clearly positive phase 3, strong supporting data, and a good explanation for the ENLIGHTEN-1 failure, I believe the market is underestimating the potential for NDA submission without the need of another phase 3. Assuming positive FDA feedback, I expect considerable upside, allowing LYRA to raise much needed cash from a strong position.
Lyra Therapeutics Inc. (LYRA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Lyra Therapeutics Inc. ever had a stock split?
Lyra Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Carmichael S. Roberts Jr. CEO | OTC PINK Exchange | 55234L204 CUSIP |
| US Country | 30 Employees | - Last Dividend | 28 May 2025 Last Split | 1 May 2020 IPO Date |
Overview
Lyra Therapeutics, Inc. is a vanguard in the biotechnology industry, emphasizing the development and commercialization of pioneering integrated drug and delivery solutions. The company zeroes in on providing localized treatment options for patients suffering from various ear, nose, and throat diseases. Its innovative XTreo technology platform stands at the forefront of its achievements, designed to administer medicines directly to the affected tissue, ensuring sustained release over extended periods with a solitary administration. Originally established as 480 Biomedical, Inc., the entity transitioned to Lyra Therapeutics, Inc. in July 2018. Since its inception in 2005, the company has been anchored in Watertown, Massachusetts, where it continues to break new ground in the field of clinical-stage biotechnology.
Products and Services
- XTreo Technology Platform
This state-of-the-art technology platform is Lyra Therapeutics' hallmark, facilitating the targeted delivery of medications directly to the pertinent tissue. The platform is engineered to sustain drug release over prolonged periods following a single administration, representing a significant leap forward in the treatment methodology for ear, nose, and throat diseases.
- LYR-210
As a prominent product candidate, LYR-210 is an anti-inflammatory implantable drug matrix devised for the treatment of chronic rhinosinusitis (CRS). It is currently in Phase III clinical trials, demonstrating the company's commitment to addressing this widespread and debilitating condition by potentially offering a novel treatment option for those afflicted.
- LYR-220
Designed for patients with CRS, with and without nasal polyps, LYR-220 expands on the platform's promise by targeting this challenging medical condition. It signifies Lyra Therapeutics' ongoing efforts to innovate and broaden its product offerings to cater to a more diverse patient population suffering from CRS.
- Collaboration Agreement with LianBio Inflammatory Limited
This strategic partnership underscores Lyra Therapeutics' aim to globalize its impact. It grants LianBio Inflammatory Limited the rights to develop and commercialize LYR-210 across several Asian markets, including mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. This collaboration not only extends the geographical reach of LYR-210 but also reflects the company's commitment to making its therapies accessible to a broader spectrum of the global population.
